FDA to Use GVKBio’s Biomarker DB in Voluntary Exploratory Data Program | GenomeWeb
NEW YORK (GenomeWeb News) - GVK Biosciences today said it has inked an agreement that will give the US Food and Drug Administration access to the company’s Clinical Biomarker Database.
Under the agreement, the FDA will use the database as part of its Voluntary Exploratory Data Submission Program and in internal research projects.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.